CBLI vs. NOVN, NOVNQ, STAB, GNCA, HTGMQ, AHPI, KLDO, VIVE, HGEN, and IGNY
Should you be buying Cleveland BioLabs stock or one of its competitors? The main competitors of Cleveland BioLabs include Novan (NOVN), NVN Liquidation (NOVNQ), Statera Biopharma (STAB), Genocea Biosciences (GNCA), HTG Molecular Diagnostics (HTGMQ), Allied Healthcare Products (AHPI), Kaleido Biosciences (KLDO), Viveve Medical (VIVE), Humanigen (HGEN), and Ignyte Acquisition (IGNY). These companies are all part of the "medical" sector.
Cleveland BioLabs (NASDAQ:CBLI) and Novan (NASDAQ:NOVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Cleveland BioLabs received 37 more outperform votes than Novan when rated by MarketBeat users. Likewise, 60.53% of users gave Cleveland BioLabs an outperform vote while only 56.37% of users gave Novan an outperform vote.
Cleveland BioLabs has a net margin of 0.00% compared to Novan's net margin of -128.61%. Cleveland BioLabs' return on equity of -32.84% beat Novan's return on equity.
In the previous week, Novan had 1 more articles in the media than Cleveland BioLabs. MarketBeat recorded 1 mentions for Novan and 0 mentions for Cleveland BioLabs. Cleveland BioLabs' average media sentiment score of 0.00 equaled Novan'saverage media sentiment score.
Cleveland BioLabs has higher earnings, but lower revenue than Novan.
5.1% of Cleveland BioLabs shares are owned by institutional investors. Comparatively, 14.5% of Novan shares are owned by institutional investors. 1.0% of Cleveland BioLabs shares are owned by insiders. Comparatively, 1.3% of Novan shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Cleveland BioLabs has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Novan has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500.
Summary
Cleveland BioLabs beats Novan on 8 of the 12 factors compared between the two stocks.
Get Cleveland BioLabs News Delivered to You Automatically
Sign up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CBLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cleveland BioLabs Competitors List
Related Companies and Tools
